Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
HERO
DV+BCG in HER2-Expressing, BCG-Naïve High-Risk NMIBC
- NCT07207824 ↗
- Recruiting
- Fudan University
- Deep
We haven't built an HCP commentary report on HERO (disitamab vedotin in HER2-expressing BCG-naïve high-risk non-muscle-invasive bladder cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on HERO so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 55 | |
| Podcasts | 34 | |
| YouTube | 26 |
The trial
ClinicalTrials.gov- Official title
- A Phase III Randomized Controlled Trial of Disitamab Vedotin (DV) Combined With Bacillus Calmette-Guérin (BCG) in BCG-Naïve Patients With HER2-Expressing, High-Risk Non-Muscle-Invasive Bladder Cancer
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Bladder (Urothelial, Transitional Cell) Cancer; NMIBC
- Interventions
- Active Comparator: BCG induction and maintenance; DV + BCG induction and maintenance
- Arms
- DV + BCG · Experimental
- BCG · Active comparator
- Enrollment
- 182 (estimated)
- Primary outcomes
- Event free survival
- Sponsor
- Fudan University
- Start
- Dec 1, 2025
- Primary completion
- Jun 1, 2030 (estimated)
- Results posted
- No
- Registry record
- NCT07207824 · updated Jul 21, 2026